WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 21'0101 Infant (under 12 months) mortality rate: 142
GDP / capita (US$): 23'5211 Child (under 5 years) mortality rate: 172

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 383  377  372  366  360  298  256  211 
Births
Surviving infants
Pop. less than 5 years 29  29  29  28  27  28  28  25 
Pop. less than 15 years 80  80  81  81  81  87  83  78 
Female 15-49 years 105  105  104  103  102  84  70  55 

Number of reported case

(Click for retrospective incidence data for Bahamas (the))
Diphtheria
Japanese encephalitis
Measles 72  484 
Mumps
Pertussis 15 
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Bahamas (the))
Vaccine year result method % card seen                                                
BCG         
DTP1          96  99*  99  99*  99*  99* 
DTP3          96  97  98  98  99  99  87  36 
DTP4          74 
IPV1         
HepB_BD         
HepB3          96  97  96  95  98 
Hib3          96  97  98  98  98  90 
JapEnc         
MCV1          92  92  91  90  94  93  99 
MCV2          72  69  73  79  47 
PCV1          96  99*  77 
PCV3          96  97  37 
Pol3          96  97  99  97  97  91  82  35 
Rota1          12 
Rota_last          10 
Rubella1          92  92  91  90  94 
TT2plus          99  98  97  95  96 
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Bahamas (the))
DTP1 96  99  99  99  99  99  95  61 
DTP3 96  97  98  98  99  99  86  36 
HepB3 96  97  96  95  98 
HepB_BD
Hib3 96  97  98  98  98  90 
MCV1 92  92  91  90  94  93  86 
MCV2 72  69  73  79  78 
PAB 99  99  99  99  99  85  71 
PCV3 96  97  37 
Pol3 96  97  99  97  97  91  82  35 
Rota_last

Number of districts in the country 16  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 69
From 80 to 89% 31
From 50 to 79% 6
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 4, 6 months; No
DTaPHibIPV 2, 4, 6 months; No
DTwP 4-5 years; Yes
DTwPHib 15 months; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HepB_Adult 1st contact, +1, +6 months; Yes
HepB_Pediatric 2, 4, 6 months; Yes
IPV 2, 4, 6 months; 4-5 years; Yes In the public sector given only to risk groups
Influenza_Adult >=15 years; Yes and adults with chronic diseases, pregnant women, health care workers, and other risk groups
Influenza_Pediatric 6 months to 18 years; Yes and children with chronic disease
MMR 1, 4-5 years; Yes
MenACWY > 2 years;
OPV 2, 4, 6 months; 4-5 years; Yes
Pneumo_conj 2, 4, 6, 15 months; Yes
Pneumo_ps > 2 years;
Td 10-12 years; Yes every 10 years
Tdap 10-12 years Yes every 10 years
Varicella 1, 4-5 years; Yes
YF travelers

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2010-2020  2010-2020  2010-2020  2010-2015  2010-2012  2'012  2'012 
Nº of districts with microplans that include activities to raise immunization coverage number   10  10 

System performance

Total Nº districts in country number 16  45  91  91  31  31  31 
Nº districts with DTP3 coverage >=80% number 16  44  91  23 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  98  100  25 
Nº districts with measles (MCV1) coverage >=95% number 10  30  35  23     
% of districts with MCV1 coverage >=95% From 0 to 100% 63  67  38  25     

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 99  100  100      100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.